Publicaciones en colaboración con investigadores/as de Johannes Gutenberg University of Mainz (28)

2023

  1. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

    Molecular cancer, Vol. 22, Núm. 1, pp. 119

  2. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 22, pp. 7141-7150

2022

  1. Biomarker Expression Profiling in Cervix Carcinoma Biopsies Unravels WT1 as a Target of Artesunate

    Cancer genomics & proteomics, Vol. 19, Núm. 6, pp. 727-739

  2. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells

    Phytomedicine, Vol. 86

2020

  1. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

  2. Liver and gastrointestinal cancers

    DRUG EFFLUX PUMPS IN CANCER RESISTANCE PATHWAYS: FROM MOLECULAR RECOGNITION AND CHARACTERIZATION TO POSSIBLE INHIBITION STRATEGIES IN CHEMOTHERAPY (ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD), pp. 197-250

2019

  1. Biopiracy versus One-World Medicine–From colonial relicts to global collaborative concepts

    Phytomedicine, Vol. 53, pp. 319-331

  2. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

2018

  1. Chemoresistance and chemosensitization in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1444-1453

  2. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

    Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412

  3. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Leukemia, Vol. 32, Núm. 8, pp. 1799-1803

  4. Molecular bases of the poor response of liver cancer to chemotherapy

    Clinics and Research in Hepatology and Gastroenterology

2017

  1. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832

  2. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 8, pp. 2359-2367

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Expanding the therapeutic spectrum of artemisinin: Activity against infectious diseases beyond malaria and novel pharmaceutical developments

    World Journal of Traditional Chinese Medicine, Vol. 2, Núm. 2, pp. 1-23

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. GOBLET: The Global Organisation for Bioinformatics Learning, Education and Training

    PLoS Computational Biology, Vol. 11, Núm. 4